✦ LIBER ✦

All Struggles Must End: The Longevity of Terrorist Groups

✍ Scribed by Vittori, Jodi

Book ID: 121007957
Publisher: Taylor and Francis Group
Year: 2009
Tongue: English
Weight: 187 KB
Volume: 30
Category: Article
ISSN: 1352-3260
DOI: 10.1080/13523260903326602

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Why Must All Good Things Come to an End?

Why Must All Good Things Come to an End? The Performance of Multiple Acquirers

✍ Conn, Robert Charlie L.; Cosh, Andy; Guest, Paul M. M.; Hughes, Alan 📂 Article 📅 2004 🏛 Social Science Electronic Publishing ⚖ 438 KB

Synthesis and Characterization of all-E-

Synthesis and Characterization of all-E-(4,4′-13C2)-Astaxanthin Strategies for Labelling the C15-End Groups of Carotenoids

✍ Frans Jos H. M. Jansen; Johan Lugtenburg 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB 👁 1 views

The all-E isomer of (4,4Ј-13 C 2 )astaxanthin (1a) has been prepared by total synthesis starting from commercially available 99% 13 C enriched acetonitrile. The labelled astaxanthin was obtained in high purity and with high isotope incorporation. For this synthesis, the C 15 + C 10 + C 15 strategy w

PRAVASTATIN THERAPY AMONG ALL ETHNIC GRO

PRAVASTATIN THERAPY AMONG ALL ETHNIC GROUPS OF CARE REDUCED PRIMARY END POINT EVENTS IN CARRIERS OF THE KIF6 719ARG ALLELE, BUT NOT IN NONCARRIERS

✍ Shiffman, Dov; Sabatine, Marc S.; Louie, Judy Z.; Rowland, Charles M.; Iakoubova 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 124 KB

PCR detection of clonal IgH and TCR gene

PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: Comparison with standard morphologic analysis and risk group classification

✍ Scrideli, Carlos Alberto ;Queiroz, Rosane Gomes de Paula ;Bernardes, Jos� Eduard 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

## Abstract ## Background The initial response to induction therapy is currently considered one of the most important prognostic factors in acute lymphoblastic leukemias (ALL). A series of methods for the detection of submicroscopic levels of residual disease in patients with ALL mainly based on P